Vdac inhibitors for treating inflammatory bowel diseases
AssigneeThe National Institute for Biotechnology In the Negev Ltd.
InventorVarda SHOSHAN-BARMATZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating inflammatory bowel disease (IBD). Particularly, the present invention relates to use of specific inhibitors of Voltage-Dependent Anion Channel (VDAC1), such as piperazine- and/or piperidine-derivatives, among others, e.g., peptides and oligonucleotides, for treating IBD.
Claims6
A method for slowing the progression of or treating inflammatory bowel disease (IBD) comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a VDAC inhibiting compound of the general Formula (Id) including any enantiomer, diastereomer, salt, and mixture thereof:
- wherein:
- Z is C1-2-perfluoroalkoxy;
- L2 is a group consisting of 4-10 atoms, apart from hydrogen atoms, wherein at least one of the atoms is nitrogen forming part of an amide group;
- and
- Y is halogen.
Dependencies are inferred from the claim text.